1. Clinical Overview
A fixed-dose combination (FDC) ophthalmic solution containing a non-selective beta-adrenergic receptor blocker (Timolol) and a selective alpha-2 adrenergic receptor agonist (Brimonidine). This combination is primarily used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The dual mechanism provides additive IOP-lowering efficacy, often with a more favorable side effect profile compared to higher doses of a single agent, and may improve patient adherence.
| Onset | Duration | Bioavailability |
|---|---|---|
| Timolol: 30 minutes. Brimonidine: 1 hour. Peak IOP reduction occurs within 2-4 hours post-instillation. | Sustained IOP reduction for up to 12 hours, supporting a twice-daily (BID) dosing regimen. | Primarily topical ocular with minimal systemic absorption. Systemic bioavailability is low (<10%) due to nasolacrimal drainage and hepatic first-pass metabolism. |
2. Mechanism of Action
The combination works via two distinct pathways to reduce aqueous humor production and may slightly increase uveoscleral outflow. Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body, reducing the formation of aqueous humor. Brimonidine stimulates alpha-2 adrenoceptors, primarily decreasing aqueous humor production and secondarily increasing uveoscleral outflow. Their effects are additive.
3. Indications & Uses
- Reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma
- Reduction of elevated IOP in patients with ocular hypertension
4. Dosage & Administration
Adult Dosage: One drop in the affected eye(s) twice daily (approximately every 12 hours). Do not exceed two times daily administration.
Administration: Wash hands before use. Tilt head back, pull lower eyelid down to form a pouch. Instill one drop. Close eyes gently and apply pressure to the nasolacrimal duct (inner corner of eye) for 1-2 minutes to minimize systemic absorption. Wait at least 5 minutes before instilling any other topical ophthalmic medication. Do not touch dropper tip to eye or any surface.
5. Side Effects
Common side effects may include:
- Ocular hyperemia (redness)
- Burning or stinging upon instillation
- Pruritus (itching) of the eye
- Foreign body sensation
- Allergic conjunctivitis
- Blurred vision
- Bitter taste following instillation
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Oral Beta-Blockers (e.g., Propranolol, Metoprolol) | Additive systemic beta-blockade; increased risk of bradycardia, AV block, heart failure. | Major |
| Calcium Channel Blockers (e.g., Verapamil, Diltiazem) | Potentiates negative inotropic and chronotropic effects; risk of severe bradycardia and heart failure. | Major |
| Digoxin | Additive effects on AV conduction; increased risk of bradycardia. | Moderate |
| Clonidine (systemic) | Additive alpha-2 agonist effects; potential for rebound hypertension if clonidine is withdrawn. | Moderate |
| MAO Inhibitors (e.g., Phenelzine, Tranylcypromine) | May potentiate the systemic vasopressor effects of brimonidine; avoid concomitant use. | Major |
| Antihypertensives (ACE inhibitors, Diuretics) | Additive hypotensive effect. | Moderate |
| Insulin, Oral Hypoglycemics | Timolol may mask tachycardia as a sign of hypoglycemia and may impair glucose recovery. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | May potentiate the sedative effects of brimonidine. | Moderate |
7. Patient Counselling
- DO wash hands before and after use.
- DO apply nasolacrimal occlusion (pressing finger on inner corner of eye) for 1-2 minutes after instillation.
- DO wait at least 5-10 minutes before instilling another eye drop.
- DO NOT touch the dropper tip to your eye, fingers, or any surface.
- DO NOT wear soft contact lenses while using this medication unless advised by your doctor (contains benzalkonium chloride).
- DO NOT stop using this medication suddenly without consulting your doctor.
- DO inform all your doctors and your dentist that you are using this eye drop.
8. Toxicology & Storage
Overdose: Ocular: Severe irritation, corneal damage. Systemic (from ingestion or excessive topical use): Bradycardia, hypotension, bronchospasm, respiratory depression, CNS depression (somnolence, lethargy, coma in children), hypothermia, hypoglycemia.
Storage: Store at room temperature (15°C to 25°C). Protect from light. Keep the bottle tightly closed when not in use. Do not freeze. Keep out of reach and sight of children. Discard the bottle 28 days after first opening. Do not use if the solution is discolored or contains particles.